FY2025 · ended Dec 31, 2025 · Revenue $456,021, -26.0% YoY · Filed Apr 1, 2026
Mangoceuticals, Inc. (MGRX) files with the SEC under industry code 8090, Services-Misc Health & Allied Services, NEC. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $456,021 and a net loss of $20.6 million. As of Jun 30, 2026 it held $228,688 in cash and investments and $279,207 in total debt.
Revenue (TTM)
$315,227
-38.9% vs year-ago TTM
Net income (TTM)
$-15.10M
-6.3% vs year-ago TTM
Operating cash flow (TTM)
$-3.89M
+33.2% vs year-ago TTM
Free cash flow
$-7.00M
EPS (TTM)
$-1.02
+65.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
16.97M
+228.3% vs prior year
Net cash
$-50,519
as of Jun 30, 2026
Operating margin
-3829.0%
FY 2026
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- MGRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Dallas, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1938046
- Former names
- MANGOCEUTICALS, INC. (until Oct 9, 2026)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $456,021 | $615,873 | $731,493 |
| Operating income | -$18.0M | -$8.0M | -$9.2M |
| Net income | -$20.6M | -$8.7M | -$9.2M |
| Diluted EPS | -$2.17 | -$4.80 | -$8.58 |
| Operating cash flow | -$5.9M | -$4.9M | -$7.0M |
| Free cash flow | — | — | -$7.0M |
| Total assets | $16.1M | $15.4M | $1.1M |
| Total liabilities | $890,568 | $1.4M | $276,039 |
| Stockholders' equity | $15.2M | $13.9M | $774,754 |
| Cash and investments | $1.5M | $58,653 | $739,006 |
| Total debt | $307,823 | $64,962 | $128,679 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Regulation FD disclosure
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Agreement ended
|
Aug 21, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 30, 2026 | Jul 28, 2026 |
All 240 Mangoceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.